| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Gamma-crystallin D, Gamma-D-crystallin, Gamma-crystallin 4, CRYGD, CRYG4 |
| Entrez GeneID | 1421 |
| WB Predicted band size | 20.7kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This CRYGD antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 73-101 amino acids from the Central region of human CRYGD. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于CRYGD抗体的3篇文献示例(内容为模拟生成，仅供参考)：
1. **文献名称**：*CRYGD Antibody Localization in Congenital Cataract Models*
**作者**：Zhang L, et al.
**摘要**：研究通过CRYGD抗体标记，分析先天性白内障患者晶状体中γD-晶状体蛋白异常聚集的机制，发现突变导致蛋白构象改变并与细胞凋亡相关。
2. **文献名称**：*CRYGD Mutation Screening Using Polyclonal Antibody in Familial Cataracts*
**作者**：Wang Y, et al.
**摘要**：开发CRYGD多克隆抗体用于家族性白内障的基因突变检测(如R58H)，证实抗体在识别致病性突变蛋白中的特异性及诊断潜力。
3. **文献名称**：*Interaction of CRYGD with αA-Crystallin Revealed by Co-Immunoprecipitation*
**作者**：Liu X, et al.
**摘要**：利用CRYGD抗体进行免疫共沉淀实验，揭示其与αA-晶状体蛋白的相互作用机制，为晶状体透明度维持提供分子依据。
注：以上为模拟文献，实际引用需查询PubMed或学术数据库获取真实数据。
CRYGD antibodies target the gamma-D crystallin protein (CRYGD), a key structural component of the eye lens essential for maintaining transparency and refractive properties. Crystallins, including the γ-crystallin family, account for up to 90% of soluble lens proteins. CRYGD, encoded by the *CRYGD* gene, is highly expressed in lens fiber cells and contributes to lens elasticity and long-term stability. Mutations in *CRYGD* are linked to hereditary cataracts, making CRYGD a critical focus in ophthalmology research.
CRYGD antibodies are vital tools for studying cataract pathogenesis, protein aggregation, and lens development. They enable detection of CRYGD expression in tissue samples via techniques like Western blotting, immunohistochemistry, and immunofluorescence. These antibodies also help investigate post-translational modifications (e.g., oxidation, truncation) associated with age-related cataracts. Commercial CRYGD antibodies are typically raised in rabbits or mice using recombinant protein fragments or synthetic peptides, with validation in human or model organism tissues.
Research using CRYGD antibodies has advanced understanding of protein misfolding mechanisms in cataracts and potential therapeutic strategies. Their specificity and reliability are crucial for distinguishing CRYGD from homologous crystallins (e.g., CRYGC) in experimental models. Ongoing studies leverage these antibodies to explore gene therapy and small-molecule interventions targeting crystallin stability.
×
